» Articles » PMID: 38892349

Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jun 19
PMID 38892349
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease affecting mostly women of child-bearing age. Immune dysfunction in SLE results from disrupted apoptosis which lead to an unregulated interferon (IFN) stimulation and the production of autoantibodies, leading to immune complex formation, complement activation, and organ damage. Lupus nephritis (LN) is a common and severe complication of SLE, impacting approximately 30% to 40% of SLE patients. Recent studies have demonstrated an alteration in mitochondrial homeostasis in SLE patients. Mitochondrial dysfunction contributes significantly to SLE pathogenesis by enhancing type 1 IFN production through various pathways involving neutrophils, platelets, and T cells. Defective mitophagy, the process of clearing damaged mitochondria, exacerbates this cycle, leading to increased immune dysregulation. In this review, we aim to detail the physiopathological link between mitochondrial dysfunction and disease activity in SLE. Additionally, we will explore the potential role of mitochondria as biomarkers and therapeutic targets in SLE, with a specific focus on LN. In LN, mitochondrial abnormalities are observed in renal cells, correlating with disease progression and renal fibrosis. Studies exploring cell-free mitochondrial DNA as a biomarker in SLE and LN have shown promising but preliminary results, necessitating further validation and standardization. Therapeutically targeting mitochondrial dysfunction in SLE, using drugs like metformin or mTOR inhibitors, shows potential in modulating immune responses and improving clinical outcomes. The interplay between mitochondria, immune dysregulation, and renal involvement in SLE and LN underscores the need for comprehensive research and innovative therapeutic strategies. Understanding mitochondrial dynamics and their impact on immune responses offers promising avenues for developing personalized treatments and non-invasive biomarkers, ultimately improving outcomes for LN patients.

Citing Articles

Intricating connections: the role of ferroptosis in systemic lupus erythematosus.

Zhao G, Li X, Zhang Y, Wang X, Deng L, Xu J Front Immunol. 2025; 16:1534926.

PMID: 39967676 PMC: 11832682. DOI: 10.3389/fimmu.2025.1534926.


Lower circulating mitochondrial DNA and increased mitokines suggest significant mitochondrial dysfunction in systemic lupus erythematosus with renal involvement.

Halfon M, Memon A, Hedelius A, Pascual M, Sundquist K, Ribi C Lupus Sci Med. 2025; 12(1).

PMID: 39900408 PMC: 11795360. DOI: 10.1136/lupus-2024-001368.


Bibliometric analysis of metformin as an immunomodulator (2013-2024).

Zhou T, Yu Y, Li L, Liu X, Xiang Q, Yu R Front Immunol. 2025; 15():1526481.

PMID: 39845945 PMC: 11750822. DOI: 10.3389/fimmu.2024.1526481.


[ Granules improves thrombocytopenia in mice with systemic lupus erythematosus by suppressing platelet autophagy the Ca/CaMKK2/AMPK/mTOR signaling pathway].

Li Y, Pang L, Shu L, Li M, Huang C Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(12):2327-2334.

PMID: 39725621 PMC: 11683354. DOI: 10.12122/j.issn.1673-4254.2024.12.08.


Immune Mechanisms and Biomarkers in Systemic Lupus Erythematosus.

Parodis I, Sjowall C Int J Mol Sci. 2024; 25(18).

PMID: 39337453 PMC: 11432324. DOI: 10.3390/ijms25189965.


References
1.
Halfon M, Bachelet D, Hanouna G, Dema B, Pellefigues C, Manchon P . CD62L on blood basophils: a first pre-treatment predictor of remission in severe lupus nephritis. Nephrol Dial Transplant. 2020; 36(12):2256-2262. DOI: 10.1093/ndt/gfaa263. View

2.
Pattingre S, Turtoi A . BAG Family Members as Mitophagy Regulators in Mammals. Cells. 2022; 11(4). PMC: 8870067. DOI: 10.3390/cells11040681. View

3.
Popov L . Mitochondrial biogenesis: An update. J Cell Mol Med. 2020; 24(9):4892-4899. PMC: 7205802. DOI: 10.1111/jcmm.15194. View

4.
Denny M, Yalavarthi S, Zhao W, Thacker S, Anderson M, Sandy A . A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010; 184(6):3284-97. PMC: 2929645. DOI: 10.4049/jimmunol.0902199. View

5.
Lee H, Lin C, Chen W, Liao H, Tsai C, Wei Y . Leukocyte mitochondrial DNA alteration in systemic lupus erythematosus and its relevance to the susceptibility to lupus nephritis. Int J Mol Sci. 2012; 13(7):8853-8868. PMC: 3430270. DOI: 10.3390/ijms13078853. View